{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:19:41Z","timestamp":1789017581498,"version":"build-2803163510"},"reference-count":42,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T00:00:00Z","timestamp":1712966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Pegaspargase (PEG) is a key component of standard regimens for acute lymphoblastic leukemia\/lymphoma (ALL) and extranodal natural killer\/T-cell lymphoma (NKTCL). Emerging evidence suggests an opportunity to decrease incidence of PEG-associated toxicities with dose capping, but evidence is limited. This study aims to evaluate whether a significant difference in PEG-associated toxicities related to dosing strategy exists and to identify patient-specific or regimen-specific factors for PEG-related toxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective analysis of PEG-associated toxicities was completed in adult patients with ALL or NKTCL who received PEG within Cancer and Leukemia Group B (CALGB) 10403 or modified dexamethasone, methotrexate, ifosfamide, L-asparaginase, etoposide (mSMILE) regimens at the UW Medical Center\/Fred Hutchinson Cancer Center. PEG-associated toxicities that occurred through 8 weeks after PEG doses were noted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-eight patients received dose-capped PEG, and 29 received noncapped PEG. Fewer all-grade and grade 3\/4 toxicities were observed in the dose-capped cohort. Grade 3\/4 toxicities observed were hepatotoxicity, hyperglycemia, hypersensitivity, and hypertriglyceridemia. In addition, fewer grade 3\/4 pancreatitis and thrombosis events occurred in the dose-capped cohort. Hypertriglyceridemia and hepatotoxicity were associated with the highest cumulative incidence proportions among all toxicities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Dose capping of PEG was associated with a similar or later median onset for most toxicities, a less heterogeneic toxicity profile, and a lower recurrence of most toxicities upon PEG rechallenge compared to the non-dose-capped cohort. Standardizing PEG dose capping in the CALGB 10403 and mSMILE regimens may translate to improved tolerance compared to a historical standard of no dose capping PEG.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552241246104","type":"journal-article","created":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T04:49:46Z","timestamp":1712983786000},"page":"534-544","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Retrospective review of the toxicities and change in dosing patterns for pegaspargase in patients with acute lymphoblastic leukemia\/lymphoma and T-cell lymphoma"],"prefix":"10.1177","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9972-4794","authenticated-orcid":false,"given":"Grace","family":"Baek","sequence":"first","affiliation":[{"name":"Fred Hutchinson Cancer Center"},{"name":"UW Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miryoung","family":"Kim","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center"},{"name":"UW Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5397-4429","authenticated-orcid":false,"given":"Madison","family":"Lee","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center"},{"name":"UW Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"O\u2019Connor","sequence":"additional","affiliation":[{"name":"UW Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Held","sequence":"additional","affiliation":[{"name":"UW Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"van der Laan","sequence":"additional","affiliation":[{"name":"University of Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan D","family":"Cassaday","sequence":"additional","affiliation":[{"name":"University of Washington School of Medicine"},{"name":"Fred Hutchinson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,4,13]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01120-1"},{"key":"e_1_3_2_3_2","first-page":"10","article-title":"Current use of asparaginase in acute lymphoblastic leukemia\/lymphoblastic lymphoma","author":"Maese L","year":"2022","unstructured":"Maese L, Rau RE. Current use of asparaginase in acute lymphoblastic leukemia\/lymphoblastic lymphoma. Front Pediatr 2022: 10: 902117.","journal-title":"Front Pediatr"},{"key":"e_1_3_2_4_2","unstructured":"NCCN Clinical Practice Guidelines in Oncology: acute lymphoblastic leukemia. Version 4.2023 https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/all.pdf."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-000858"},{"key":"e_1_3_2_6_2","volume-title":"Oncaspar (package insert)","author":"Servier Pharmaceuticals LLC","year":"2024","unstructured":"Servier Pharmaceuticals LLC. Oncaspar (package insert). Boston: Servier Pharmaceuticals LLC, 2024."},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-10-881961"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-431460"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-128435"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4782-y"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002132"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.2147\/BLCTT.S245210"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2017.12.013"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-019-09971-2"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1765239"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.596963"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.290"},{"key":"e_1_3_2_18_2","article-title":"Hyperglycemia during induction therapy for acute lymphoblastic leukemia is temporally linked to pegaspargase administration","author":"Pollock NI","year":"2021","unstructured":"Pollock NI, Flamand Y, Zhu J, et al. Hyperglycemia during induction therapy for acute lymphoblastic leukemia is temporally linked to pegaspargase administration. Pediatr Blood Cancer 2021: e29505.","journal-title":"Pediatr Blood Cancer"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155219833438"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26555"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-045351"},{"key":"e_1_3_2_22_2","unstructured":"Tiao E Patzke C Lawson J et al. Impact of pegaspargase dose capping on incidence of pegaspargase-related adverse events in adults (Poster) https:\/\/archive.hshsl.umaryland.edu\/bitstream\/handle\/10713\/12199\/SOP_Tiao%20_2020.pdf?sequence=1&isAllowed=y."},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155219838316"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1105369"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1680839"},{"key":"e_1_3_2_26_2","unstructured":"Knapp K Patel S Zacholski K et al. Toxicity evaluation of dose-capped versus full-dose pegaspargase in adult acute lymphoblastic leukemia (ALL) induction [Abstract]. HOPA Annual Conference. 2021."},{"key":"e_1_3_2_27_2","unstructured":"NCCN Clinical Practice Guidelines in Oncology: T-cell lymphomas. Version 1.2023 https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/t-cell.pdf."},{"key":"e_1_3_2_28_2","unstructured":"National Institutes of Health National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. 2017 https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5\u2009\u00d7\u200911.pdf."},{"key":"e_1_3_2_29_2","volume-title":"The statistical analysis of failure time data","author":"Kalbfleisch JD","year":"1980","unstructured":"Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley and Sons, Inc., 1980."},{"key":"e_1_3_2_30_2","volume-title":"Analysing survival data from clinical trials and observational studies","author":"Marubini E","year":"1995","unstructured":"Marubini E, Balsecchi MG. Analysing survival data from clinical trials and observational studies. New York: John Wiley and Sons, Inc., 1995."},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1586\/17512433.1.3.391"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.4103\/0970-0218.66859"},{"key":"e_1_3_2_33_2","article-title":"CLO22-066: toxicity of a modified PEG-asparaginase based SMILE regimen is comparable to L-asparaginase based SMILE in a non-Asian population","author":"Melendez YP","unstructured":"Melendez YP, Mahmoud A, Caddell R, et al. CLO22-066: toxicity of a modified PEG-asparaginase based SMILE regimen is comparable to L-asparaginase based SMILE in a non-Asian population. JNCCN. Epub ahead of print 24 Apr 2023. DOI: https:\/\/doi.org\/10.6004\/jnccn.2021.7185.","journal-title":"JNCCN"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1590\/2359-3997000000068"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2021.100908"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1811864"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2022.2102621"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-112604"},{"key":"e_1_3_2_39_2","first-page":"328","article-title":"Thromboembolism prophylaxis in adult patients with acute lymphoblastic leukemia treated in the GRAALL-2005 study","volume":"136","author":"Orvain C","year":"2020","unstructured":"Orvain C, Balsat M, Tavernier E, et al. Thromboembolism prophylaxis in adult patients with acute lymphoblastic leukemia treated in the GRAALL-2005 study. Blood 2020; 136: 328\u2013338.","journal-title":"Blood"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00314-9"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.2217\/fon.15.114"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2023.2171267"},{"key":"e_1_3_2_43_2","first-page":"100357","article-title":"Acute pancreatitis following L-asparaginase in acute lymphoblastic leukemia","volume":"18","author":"M\u2019harzi S","year":"2022","unstructured":"M\u2019harzi S, Elouali A, Lahrache K, et al. Acute pancreatitis following L-asparaginase in acute lymphoblastic leukemia. Leuk Res Rep 2022; 18: 100357.","journal-title":"Leuk Res Rep"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552241246104","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552241246104","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552241246104","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:29:45Z","timestamp":1777688985000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552241246104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,13]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1177\/10781552241246104"],"URL":"https:\/\/doi.org\/10.1177\/10781552241246104","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,13]]}}}